Cargando…

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies

BACKGROUND: Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery. METHOD: Pharmacokinetic data were obtain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Xiaohua, Chen, Xuejun, Kuligowski, Michael E., Liu, Xing, Liu, Xiang, Cimino, Evan, McGee, Ryan, Yeleswaram, Swamy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200345/ https://www.ncbi.nlm.nih.gov/pubmed/33982267 http://dx.doi.org/10.1007/s40257-021-00610-x

Ejemplares similares

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
por: Bissonnette, Robert, et al.
Publicado: (2022)

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2023)

Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
por: Owji, Shayan, et al.
Publicado: (2022)

Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis
por: Scuron, Monika D., et al.
Publicado: (2021)

Ruxolitinib cream for the treatment of cutaneous sarcoidosis
por: Smith, Jeffrey S., et al.
Publicado: (2023)

Treatment of cutaneous lupus with topical ruxolitinib cream
por: Park, Jonathan J., et al.
Publicado: (2022)

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
por: Yeleswaram, Swamy, et al.
Publicado: (2020)

Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
por: Bloudek, Lisa, et al.
Publicado: (2022)

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
por: Appeldoorn, T. Y. J., et al.
Publicado: (2023)

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm
por: Langmuir, Peter, et al.
Publicado: (2020)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
por: Pope, Eleanor, et al.
Publicado: (2022)

Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream
por: Nugent, Shannon, et al.
Publicado: (2022)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab
por: Khang, Juna, et al.
Publicado: (2023)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Coccidioidomycosis in Patients Treated With Ruxolitinib
por: Kusne, Yael, et al.
Publicado: (2020)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Ruxolitinib and Severe COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Letter in response to the case report “Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis”
por: Teklu, Meron, et al.
Publicado: (2023)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
por: Ji, Tao, et al.
Publicado: (2022)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

Ruxolitinib withdrawal due to the COVID-19
por: Lucijanic, Marko, et al.
Publicado: (2021)

Ruxolitinib: Extreme thrombocytosis: case report
Publicado: (2021)

Topical ruxolitinib for the treatment of granuloma faciale
por: Wong, Alan, et al.
Publicado: (2023)

Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
por: Howell, Michael D., et al.
Publicado: (2023)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Ruxolitinib for Therapy of Graft-versus-Host Disease
por: Neumann, Thomas, et al.
Publicado: (2019)

Delayed granulomatous eruption of the nose associated with ruxolitinib
por: Brown, Margaret, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_alo4n7s5gh1c6j6qof1vu23neh